Status:

COMPLETED

Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries

Lead Sponsor:

Novo Nordisk A/S

Conditions:

Congenital Bleeding Disorder

Haemophilia A

Eligibility:

MALE

6-18 years

Brief Summary

This study is conducted in Africa and Asia. The aim of this study is to evaluate in the participating countries the orthopaedic status and the degree of arthropathy of severe haemophilia patients in g...

Eligibility Criteria

Inclusion

  • Patient (and/or parents or the patient's legally acceptable representative, if applicable) must give signed and dated informed consent before enrolment in the study
  • Male patients at least 6 years old with diagnosis of severe congenital haemophilia A or B with or without inhibitors
  • Patients receiving on demand replacement factors/bypassing agents therapy

Exclusion

  • Clinically relevant coagulation disorders other than congenital haemophilia A or B
  • Patients on currently active treatment for HCV (Hepatitis C Virus) or HIV (Human Immune Deficiency Virus) infections

Key Trial Info

Start Date :

January 1 2012

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 1 2012

Estimated Enrollment :

282 Patients enrolled

Trial Details

Trial ID

NCT01503567

Start Date

January 1 2012

End Date

September 1 2012

Last Update

January 18 2017

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Novo Nordisk Investigational Site

Bangalore, India, 560001

2

Novo Nordisk Investigational Site

Casablanca, Morocco, 20000

3

Novo Nordisk Investigational Site

Muscat, Oman

4

Novo Nordisk Investigational Site

Sandton, South Africa, 2146